Symbols

DARE

Dare Bioscience·NASDAQ

--(--)

DARE fundamentals

DARE Q4 2025 Earnings

Dare Bioscience (DARE) released its earnings on Mar 26, 2026: revenue was 1.02M (YoY --), beat estimates; EPS was 0.03 (YoY --), beat estimates.

Revenue / YoY

1.02M

EPS / YoY

0.03

Report date

Mar 26, 2026

DARE Earnings Call Summary for Q4,2025

Breakthrough Launch: DARE to PLAY, the first FDA-GMP compliant topical sildenafil cream, begins national dispensing Q2 2026, backed by clinical data showing 10-minute efficacy.
Dual Strategy Success: 503B commercialization and FDA pathway advancement for multiple products, including DARE to RECLAIM (2027 launch) and Ovaprene (Phase III data 2027).
Financial Strength: $24.7M cash, $19.4M non-dilutive funding, and Q2 2026 revenue from DARE to PLAY and DARE to RESTORE.
Innovative Pipeline: Addresses $2.5B-$4.5B hormone therapy market, $6M HPV untreated population, and growing demand for non-hormonal contraception.

Earnings

EPS

Revenue

Revenue & Expenses

DARE has released its 2025 Q4 earnings report, with revenue of 1.02M, reflecting a YoY change of 1708.36%, and net profit of -1.44M, showing a YoY change of 73.82%. The Sankey diagram below clearly presents DARE's revenue sources and cost distribution.

Key Indicators

Dare Bioscience (DARE) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Dare Bioscience (DARE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Dare Bioscience (DARE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Dare Bioscience (DARE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown